肽SMIM30通过诱导SRC/YES1膜锚定及MAPK通路激活促进肝细胞癌发展
研究在4种癌细胞系中用RPS6抗体行RIP-seq,发现LINC00998编码短肽SMIM30,该肽而非其RNA通过调控细胞增殖和迁移促进肝细胞癌肿瘤发生,其水平与患者不良生存相关。SMIM30由c-Myc转录,驱动SRC/YES1膜锚定并激活下游MAPK通路。
要点
- LINC00998编码的短肽SMIM30促进肝细胞癌增殖、迁移和肿瘤发生。
- SMIM30水平与肝细胞癌患者不良生存相关。
- SMIM30驱动SRC/YES1膜锚定并激活下游MAPK通路。
核心结论
- 研究揭示了ncRNA编码肽促进肝细胞癌肿瘤发生的新机制,并提示这些肽可作为肝细胞癌治疗新靶点及诊断和预后新生物标志物。
研究设计与样本
- 研究对4种癌细胞系用抗核糖体蛋白S6(RPS6)抗体行RNA免疫沉淀后高通量测序(RIP-seq)。
- 聚焦长链非编码RNA LINC00998,用qPCR和公共数据库评估其在肝细胞癌患者中的表达水平。
- 构建特殊载体确认LINC00998的编码潜力,并探索LINC00998编码肽在肿瘤生长和转移中的功能与机制。
主要发现
- 发现许多lncRNA在癌细胞中与RPS6结合。
- LINC00998编码一个小内源性肽SMIM30。
- SMIM30而非其RNA本身通过调控细胞增殖和迁移促进肝细胞癌肿瘤发生,其水平与患者不良生存相关。
- SMIM30由c-Myc转录,驱动非受体酪氨酸激酶SRC/YES1的膜锚定。
- SRC/YES1激活下游MAPK信号通路。
临床怎么用
- 原文结论认为这些肽可作为肝细胞癌治疗新靶点及诊断和预后新生物标志物,未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Growing evidence shows that some non-coding RNAs (ncRNAs) contain small open reading frames (smORFs) that are translated into short peptides. Herein, we aimed to determine where and how these short peptides might promote hepatocellular carcinoma (HCC) development. METHODS: We performed an RNA-immunoprecipitation followed by high-throughput sequencing (RIP-seq) assay with an antibody against ribosomal protein S6 (RPS6) on 4 cancer cell lines. Focusing on 1 long non-coding RNA (lncRNA), LINC00998, we used qPCR and public databases to evaluate its expression level in patients with HCC. Special vectors were constructed to confirm its coding potential. We also explored the function and mechanism of LINC00998-encoded peptide in tumor growth and metastasis. RESULTS: We discovered that many lncRNAs bind to RPS6 in cancer cells. One of these lncRNAs, LINC00998, encoded a small endogenous peptide, termed SMIM30. SMIM30, rather than the RNA itself, promoted HCC tumorigenesis by modulating cell proliferation and migration, and its level was correlated with poor survival in patients with HCC. Furthermore, SMIM30 was transcribed by c-Myc and then drove the membrane anchoring of the non-receptor tyrosine kinases SRC/YES1. Moreover, the downstream MAPK signaling pathway was activated by SRC/YES1. CONCLUSIONS: Our results not only unravel a new mechanism of HCC tumorigenesis promoted by ncRNA-encoded peptides, but also suggest that these peptides can serve as a new target for HCC cancer therapy and a new biomarker for HCC diagnosis and prognosis. LAY SUMMARY: Very little is known about how peptides activate signaling pathways that play a crucial role in diseases such as cancer. Specifically, we reported on a conserved peptide encoded by LINC00998, SMIM30. This peptide promoted the tumorigenesis of hepatocellular carcinoma (HCC) by modulating cell proliferation and migration. Of note, it bound the non-receptor tyrosine kinases, SRC/YES1, to drive their membrane anchoring and phosphorylation, activating the downstream MAPK signaling pathway. Our work not only unravels a new mechanism of HCC tumorigenesis promoted by peptides, but also demonstrates how the peptide works to activate a signaling pathway.
引用
- Pang Y, Liu Z, Han H, et al. Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation. J Hepatol. 2020. PMID: 32461121. doi:10.1016/j.jhep.2020.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。